Skip to main content
. Author manuscript; available in PMC: 2016 Jun 21.
Published in final edited form as: Nat Nanotechnol. 2015 Dec 21;11(3):295–303. doi: 10.1038/nnano.2015.292

Figure 5. eCPMV immunotherapy is successful in metastatic breast, colon, and ovarian carcinoma models.

Figure 5

a, Mice challenged with 4T1 breast tumours and intratracheally injected with PBS rapidly developed (IVIS images) and succumbed (Kaplan-Meier) to metastatic lung tumours beginning on day 24 post-surgical removal of primary tumour, whereas tumour development was delayed and survival significantly extended in mice receiving intratracheal injection of eCPMV (n = 8 eCPMV, 5 PBS). b, Mice bearing intradermal flank CT26 colon tumours also responded to direct injection of eCPMV (arrows indicate treatment days) with significantly delayed growth when compared to PBS-injected controls (n = 5/group). c, eCPMV also proved successful as a therapy for ID8-Defb29/Vegf-A ovarian cancer-challenged mice, significantly improving survival when injected IP relative to PBS-injected controls (n = 4 eCPMV, 11 PBS). eCPMV-treated mice displayed no visible ascites on day 42 post-challenge while PBS-treated controls had reached endstage criteria. Survival experiments utilised the log-rank Mantel-Cox test for survival analysis and flank tumour growth curves were analysed using two-way ANOVA, with p <0.05 as *, p <0.01 as **, and p <0.001 as ***.